Dynavax (DVAX) Price & Analysis

Compare

2,472 Followers

DVAX Stock Chart & Stats

$15.50

-$0.11(-0.86%)

At close: Jan 08 4:00 PM EST

$15.50

-$0.11(-0.86%)

Day’s Range― - ―

52-Week Range$9.20 - $15.73

Previous CloseN/A

Volume272.71K

Average Volume (3M)3.27M

Market Cap

$1.82B

Enterprise Value$1.94B

Total Cash (Recent Filing)$647.82M

Total Debt (Recent Filing)$285.02M

Price to Earnings (P/E)―

Beta0.47

Next Earnings

Feb 19, 2026

EPS Estimate

0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.21

Shares Outstanding117,424,965

10 Day Avg. Volume2,850,365

30 Day Avg. Volume3,266,142

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)2.78

Price to Sales (P/S)5.99

P/FCF Ratio27.60

Enterprise Value/Market Cap1.07

Enterprise Value/Revenue5.88

Enterprise Value/Gross Profit7.07

Enterprise Value/Ebitda-75.83

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.53

Revenue Forecast (FY)$392.42M

Bulls Say, Bears Say

Bulls Say

AcquisitionSanofi's announced acquisition at $15.50 per share provides an exit path for shareholders and validates the strategic value of Dynavax's vaccine portfolio.

Capital ReturnsAuthorization of a $100 million share repurchase signals management confidence in cash generation and creates a direct mechanism to return capital to shareholders.

Market Share And Retail PenetrationDynavax's U.S. hepatitis B market share increasing to 46 percent and capturing about 63 percent of the retail segment indicates strong commercial traction that can support revenue expansion.

Bears Say

Analyst SentimentAnalyst recommendation downgrade to Market Perform reduces sell-side support and may limit buying interest from institutional investors.

Licensing And Contingent LiabilitiesLicensing agreements with future payment commitments for the oral vaccine program create potential financial exposure if the candidate fails to meet development milestones.

Valuation GapDeal price sits below independent net present value estimates for the vaccine franchise, implying shareholders may receive a lower-than-expected premium on the transaction.

Dynavax News

OneSpaWorld to replace Dynavax in S&P 600 at open on 2/10

Sanofi (SNY) is acquiring Dynavax Technologies (DVAX) in a deal expected to be completed soon pending final closing...

8d ago

OSW

SNY

Dynavax Completes Merger and Prepares Nasdaq Delisting

Dynavax ( ($DVAX) ) has issued an announcement. Dynavax is a biopharmaceutical company focused on developing and commercializing...

3d ago

DVAX

Dynavax Agrees to Be Acquired by Sanofi in Merger

Dynavax ( ($DVAX) ) has shared an update. On December 23, 2025, Dynavax entered into a merger agreement...

2M ago

DVAX

Dynavax, Inhibikase and More: Stocks Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($DVAX) ) and ( ($IKT) ). Here is a breakdown...

2M ago

IKT

DVAX

KB Home downgrade, Costco upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

KBH

COST

Dynavax downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Dynavax (DVAX) to Market Perform from Outperform after Sanofi (SNY) announced it will acquire the...

2M ago

DVAX

Morning Movers: Intel slipping ahead of holiday shortened-session

Stock index futures are little changed ahead of the holiday shortened session after the benchmark S&P 500 set...

2M ago

NKE

SNY

Dynavax jumps 37% to $15.31 after buyout offer from Sanofi

06:34 EST Dynavax (DVAX) jumps 37% to $15.31 after buyout offer from Sanofi (SNY) Published first on TheFly...

2M ago

SNY

DVAX

Sanofi to acquire Dynavax for $15.50 per share in cash, or $2.2B

Sanofi (SNY) announced that it has entered into an agreement to acquire Dynavax Technologies (DVAX). The acquisition augments...

2M ago

SNY

DVAX

Sanofi (SNY) Acquires Dynavax in $2.2 Billion Deal after FDA Rebuff

Sanofi ($SNY) said it will buy Dynavax Technologies ($DVAX) for about $2.2 billion in cash to grow its...

2M ago

SNY

DVAX

Dynavax Technologies Reports Strong Q3 Earnings and Strategic Growth

Dynavax Technologies (($DVAX)) has held its Q3 earnings call. Read on for the main highlights of the call....

3M ago

DVAX

Dynavax’s Promising Growth and Strategic Initiatives Justify Buy Rating with $25 Target

TD Cowen analyst Phil Nadeau has maintained their bullish stance on DVAX stock, giving a Buy rating today....

3M ago

DVAX

Dynavax reports Q3 EPS 21c vs. 12c last year

Reports Q3 revenue $94.88M, consensus $94M. “In Q3 2025, we delivered important progress across our strategic initiatives, including...

3M ago

DVAX

Dynavax enters license agreement for Vaxart’s oral COVID-19 vaccine program Vaxart

Dynavax Technologies (DVAX) and Vaxart (VXRT) announced that they have entered into an exclusive, worldwide license and collaboration...

3M ago

DVAX

VXRT

DVAX FAQ

What was Dynavax Technologies’s price range in the past 12 months?

Dynavax Technologies lowest stock price was $9.20 and its highest was $15.73 in the past 12 months.

What is Dynavax Technologies’s market cap?

Dynavax Technologies’s market cap is $1.82B.

When is Dynavax Technologies’s upcoming earnings report date?

Dynavax Technologies’s upcoming earnings report date is Feb 19, 2026 which is in 6 days.

How were Dynavax Technologies’s earnings last quarter?

Dynavax Technologies released its earnings results on Oct 24, 2025. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.126 by $0.084.

Is Dynavax Technologies overvalued?

According to Wall Street analysts Dynavax Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Dynavax Technologies pay dividends?

Dynavax Technologies does not currently pay dividends.

What is Dynavax Technologies’s EPS estimate?

Dynavax Technologies’s EPS estimate is 0.08.

How many shares outstanding does Dynavax Technologies have?

Dynavax Technologies has 117,424,965 shares outstanding.

What happened to Dynavax Technologies’s price movement after its last earnings report?

Dynavax Technologies reported an EPS of $0.21 in its last earnings report, beating expectations of $0.126. Following the earnings report the stock price went up 1.06%.

Which hedge fund is a major shareholder of Dynavax Technologies?

Currently, no hedge funds are holding shares in DVAX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Dynavax Stock Smart Score

Underperform

Fundamentals

Return on Equity

-7.14%

Trailing 12-Months

Asset Growth

-10.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.